Moraine police offering safety program for seniors, others
The Moraine Police Department is reminding the community it offers a service for certain residents to have extra safety measures.
According to the department, residents who are at least 65 years old with 'serious medical conditions' and live alone, and individuals with Alzheimer's, Autism, Dementia or developmental disorders are among those who can participate.
'Through MSSI, our Police and Fire Departments can quickly access critical information using secure databases, ID bracelets, and lock boxes — ensuring help gets where it's needed fast,' said MPD.
Moraine police said the program is voluntary. To enroll in the program, call Moraine Police Department at 937-535-1166, ask for Sergeant Dyer and reference the program.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
11 hours ago
- Yahoo
Alzheimer's disease market to reach $17bn across 8MM by 2033
The Alzheimer's disease market is expected to grow at a high compound annual growth rate (CAGR) of 21.8% from $2.4bn in 2023 to $17bn by 2033 across the eight major markets (8MM: the China, France, Germany, Japan, Italy, Spain, the UK and the US), according to GlobalData's recent report, Alzheimer's Disease: Eight-Market Drug Forecast and Market Analysis - Update. The major driving factors of this growth include the ageing global population, which will lead to an increase in prevalent cases, the entry of expensive disease-modifying therapies (DMTs) into the market, which will likely result in increased treatment rates as more options become available, and the launch of novel symptomatic therapies including the first US Food and Drug Administration (FDA)-approved therapies for the treatment of agitation and psychosis associated with Alzheimer's. A major focus of research and development in the Alzheimer's therapeutic space is preventing the accumulation of amyloid beta (Aβ). Despite many historical failures, this strategy has come to fruition for drug developers in recent years with the entry of the first DMTs to the market. The FDA approved Eisai/Biogen's Leqembi (lecanemab) in January 2023 and Lilly's Kisunla (donanemab) in July 2024, and both drugs have since been approved in Japan, China and the UK. In April 2025, after multiple delays, the European Medicines Agency approved Leqembi in a restricted population compared with the US, preventing it from being prescribed to patients who are APOE4 homozygotes [individuals who have inherited two copies of the APOE4 gene variant, one from each parent, increasing their likelihood of developing the disease]. Although the approval of the first DMTs for the treatment of Alzheimer's is a significant step forward, a key limiting factor in their uptake has been their integration into clinical practice so that they can be widely available for patients. Frequent intravenous (IV) administration places a high burden on care settings in which the drug can be administered, and access to positron emission tomography and magnetic resonance imaging (MRI) scans is a key economic and operational limiting factor for access to these drugs. In addition to logistical factors, these new DMTs are significantly more expensive than the current highly genericised symptomatic treatments used in the management of Alzheimer's, providing a further access challenge in the form of reimbursement/payer restrictions. Indeed, the Japanese Central Social Insurance Medical Council (Chuikyo) recently approved the cost-effectiveness assessment results for Leqembi, recommending a 15% price reduction, with the price change expected to come into effect from 1 November 2025. The final reimbursement guidance for Leqembi and Kisunla in the UK, published in June 2025 following two previous rejections, is that neither drug is recommended for use on the NHS. Developers are investigating alternative routes of administration so that patients will not require multiple lengthy IV infusions to be treated. Eisai and Biogen are currently evaluating a subcutaneous formulation of Leqembi, and Eli Lilly is developing a second anti-Aβ monoclonal antibody (mAb), remternetug, which can also be administered subcutaneously. Additionally, there are several oral late-stage pipeline products with a variety of mechanisms of action that, if approved, should be easier to integrate into clinical practice and therefore be more widely accessible for patients. In clinical trials, these oral products have not been associated with amyloid-related imaging abnormalities, the key side effect associated with the anti-Aβ mAbs that requires MRI monitoring, which would further improve access to these drugs. Overall, DMTs are expected to dominate the global Alzheimer's market, contributing 69.2% of the market by 2033, with drugs targeting Aβ making up the majority of this. GlobalData forecasts that Leqembi and Kisunla could generate global sales of approximately $2.9 billion and $2.3 billion, respectively, by 2033. While the market is projected to experience strong growth throughout the forecast period across the 8MM, unmet needs beyond access to treatment will remain. The rates of diagnosis and treatment are low across all stages of the disease, so there is an unmet need for accurate, easy-to-use diagnostic tests, and for biomarkers that can be used for patient classification and the assessment of treatment response. While blood-based biomarkers are now being used fairly routinely in clinical trials and research, they have not yet entered routine clinical practice, although advances are being made with the first FDA approval of a blood test for diagnosis, Fujirebio's Lumipulse G pTau 217/ß-Amyloid 1-42 Plasma Ratio, in May 2025. Additionally, the new DMTs are only considered to be moderately effective, so a significant opportunity remains for more effective DMTs that do not just slow progression but also stop the disease, with prevention the end goal. Beyond DMTs, drugs that can effectively improve cognition in the late stages of disease, as well as more effective options for secondary symptoms such as agitation and psychosis, also provide an opportunity for developers. Key opinion leaders interviewed by GlobalData did not believe there will ever be one product that could cure Alzheimer's. Rather, they consistently noted that the future of treatment will entail the combinatory use of preventative, symptomatic and disease-modifying products. Despite the significant anticipated growth of the market, activity remains high and there will be many opportunities for developers. "Alzheimer's disease market to reach $17bn across 8MM by 2033" was originally created and published by Clinical Trials Arena, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.
Yahoo
12 hours ago
- Yahoo
JUST PUBLISHED: Audrey Kuhn's Poetic Journey Through Love, Loss, and Resilience Amid Alzheimer's and Pandemic Struggles
Audrey Kuhn's poignant reflections on love, loss, and faith, published by Palmetto Publishing, illuminate resilience amid Alzheimer's and caregiving challenges. God's Voice Through the Despair Charleston, SC, Aug. 13, 2025 (GLOBE NEWSWIRE) -- God's Voice Through the Despair, authored by Audrey L. Kuhn, unveils a deeply personal journey through love, loss, and faith amid the trials of Alzheimer's, a global pandemic, and the challenges of caregiving. Audrey's narrative captures her experience as a devoted caregiver for her husband, who faces the devastating effects of Alzheimer's. Over 260 days of separation due to pandemic restrictions test her resilience, forcing her to confront the emotional weight of watching her beloved partner gradually fade away. In her darkest moments, Audrey finds solace through poetry, beginning with the poignant piece 'Little Tears,' which ignites a cascade of reflections that articulate her innermost feelings of sorrow and hope. Audrey L. Kuhn's verses explore intricate themes of love, loss, and the search for meaning amid chaos. Each poem serves as a testament to her strength, revealing the beauty of nature and the spiritual lessons learned through adversity. Her words resonate with the struggles of caregiving, encapsulating vulnerability and the courage needed to face each day. As she navigates the complexities of her husband's illness, Audrey's unwavering faith becomes her guiding light, offering comfort not only to herself but also to others grappling with similar challenges. God's Voice Through the Despair culminates in a heartfelt farewell, a final expression of love that transcends the pain of separation. This collection stands as a beacon of hope for anyone enduring the trials of caregiving, loss, and the quest for divine guidance. Audrey L. Kuhn invites readers to embrace their own narratives, reminding them that even in the darkest moments, they are never truly alone. Her journey serves as a source of comfort and inspiration, affirming the indomitable power of resilience, love, and faith. God's Voice Through the Despair is available for purchase online at and About the Author: Audrey L. Kuhn, a native of Lancaster County, Pennsylvania, is the fifth of seven children from a conservative, faith-rooted family. Her writings reflect her resilient character and compassionate spirit. Inspired by the beauty of creation, her poetry explores themes of life, death, and beyond. Many of her poems have been shared at church gatherings, funerals, and in collaborative works like Poems and Harp for the Soul. Known for her heartfelt verses, Audrey's work offers comfort to those experiencing grief or loss. Her book, God's Voice Through the Despair, showcases her enduring faith and spiritual insight. Media Contact: poemsbyaudrey@ Available for interviews: Author, Audrey L. Kuhn Attachment God's Voice Through the Despair CONTACT: Leah Joseph Palmetto Publishing publicity@
Business Wire
15 hours ago
- Business Wire
AleraCare and PURE Healthcare Announce Intent to Merge
PHOENIX & TAYLORSVILLE, Utah--(BUSINESS WIRE)-- AleraCare, a leading provider of infusion and specialty pharmacy services across the U.S., and PURE Healthcare, a leading national medical group that delivers healthcare services for individuals with complex chronic conditions such as rheumatoid arthritis, Crohn's disease, multiple sclerosis, Alzheimer's disease and other autoimmune conditions, today announced that the businesses have entered into a definitive merger agreement. Terms of the transaction were not disclosed. The proposed merger creates an unprecedented opportunity to provide high-quality patient care, improve clinical outcomes and enhance the availability of infusion services that lower the overall cost to the healthcare system overall. Founded in 2019, AleraCare's core lines of business include ambulatory infusion centers, home infusion therapy and specialty pharmacy. Administered at convenient, accessible, patient-first locations, AleraCare is focused on maintaining trusted-partner status with physicians, payors, drug distributors and pharmaceutical manufacturers. The company has rapidly expanded to over 30 ambulatory infusion centers across the country and is a provider-of-choice for infusion services to high-need and medically complex populations. Pure Healthcare, founded in 2018, is on a mission to transform the healthcare industry by making infusion therapy more affordable and accessible—while delivering a personalized, patient-centered experience. Pure specializes in treating chronic and autoimmune conditions such as Alzheimer's disease, multiple sclerosis, and rheumatoid arthritis, offering innovative, high-quality care tailored to individual needs. Its flagship offering, Pure Infusion Suites, has expanded to 43 locations across 14 states. These state-of-the-art suites prioritize patient comfort with private rooms, snacks, and entertainment, all while significantly lowering the cost of infusion services. Pure Healthcare also alleviates the administrative burden for referring providers by supporting patient authorizations and fostering strong partnerships with insurers, ensuring a seamless and efficient care journey from referral to treatment. The transaction is expected to close in the fourth quarter of 2025, and remains subject to customary closing conditions, including the expiration or termination of the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976. Holland & Knight is serving as legal counsel for AleraCare. Kunzler Bean & Adamson is serving as legal counsel and Cantor Fitzgerald is acting as financial advisor for PURE Healthcare. About AleraCare AleraCare is a leading provider of infusion treatments and pharmacy services for high-need and medically complex populations. The company's core lines of business include ambulatory infusion centers, home infusion therapy and specialty pharmacy. AleraCare provides care to patients in over 30 locations across six states throughout the U.S., including Arizona, California, Colorado, Idaho, New Mexico and Utah. For more information, please visit About PURE Healthcare Pure Healthcare, founded by BUILD Capital Partners in 2018, is a national medical group dedicated to reducing healthcare costs and improving outcomes for patients with complex chronic and autoimmune conditions like rheumatoid arthritis, Crohn's disease, multiple sclerosis, and Alzheimer's. As a market leader in infusion therapy, Pure Healthcare operates Pure Infusion Suites alongside specialty clinics in rheumatology and neurology, including Memory Treatment Centers and Montana Arthritis Centers. Through strategic payer partnerships, streamlined patient authorizations, and a commitment to personalized, high-quality care, Pure Healthcare delivers scalable value to patients, providers, and payers nationwide. Learn more at
